Druggability of Intrinsically Disordered Proteins.

Although the proteins in all the current major classes considered to be druggable are folded in their native states, intrinsically disordered proteins (IDPs) are becoming attractive candidates for therapeutic intervention by small drug-like molecules. IDPs are challenging targets because they exist as ensembles of structures, thereby making them unsuitable for standard rational drug design approaches, which require the knowledge of the three-dimensional structure of the proteins to be drugged. As we review in this chapter, several different small molecule strategies are currently under investigation to target IDPs, including: (i) to stabilise IDPs in their natively disordered states, (ii) to inhibit interactions with ordered or disordered protein partners, and (iii) to induce allosteric inhibition. In this context, biophysical techniques, including in particular nuclear magnetic resonance (NMR) spectroscopy and small-angle X-ray scattering (SAXS) coupled with molecular dynamics simulations and chemoinformatics approaches, are increasingly used to characterize the structural ensembles of IDPs and the specific interactions that they make with their binding partners. By analysing the results of recent studies, we describe the main structural features that may render IDPs druggable, and describe techniques that can be used for drug discovery programs focused on IDPs.

[1]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[2]  R. Pappu,et al.  Versatility from Protein Disorder , 2012, Science.

[3]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[4]  Christopher J. Oldfield,et al.  Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners , 2008, BMC Genomics.

[5]  Michele Vendruscolo,et al.  Chemical kinetics for drug discovery to combat protein aggregation diseases. , 2014, Trends in pharmacological sciences.

[6]  Kurt Wüthrich,et al.  Nmr in drug discovery , 2002, Nature Reviews Drug Discovery.

[7]  Kunal Patel,et al.  De novo design of self-assembled hexapeptides as β-amyloid (Aβ) peptide inhibitors. , 2014, ACS chemical neuroscience.

[8]  T. Blundell,et al.  Structural biology in fragment-based drug design. , 2010, Current opinion in structural biology.

[9]  Sara Linse,et al.  Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides , 2014, Proceedings of the National Academy of Sciences.

[10]  C. Lipinski Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[11]  P. Chène,et al.  Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. , 2004, Molecular cancer research : MCR.

[12]  Michele Vendruscolo,et al.  Atomic structure and hierarchical assembly of a cross-β amyloid fibril , 2013, Proceedings of the National Academy of Sciences.

[13]  A Keith Dunker,et al.  Drugs for 'protein clouds': targeting intrinsically disordered transcription factors. , 2010, Current opinion in pharmacology.

[14]  Christopher J. Oldfield,et al.  Classification of Intrinsically Disordered Regions and Proteins , 2014, Chemical reviews.

[15]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[16]  Marc S. Cortese,et al.  Rational drug design via intrinsically disordered protein. , 2006, Trends in biotechnology.

[17]  H. Dyson,et al.  Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.

[18]  M. Blackledge,et al.  Structural characterization of flexible proteins using small-angle X-ray scattering. , 2007, Journal of the American Chemical Society.

[19]  P. Hajduk,et al.  NMR-based screening in drug discovery , 1999, Quarterly Reviews of Biophysics.

[20]  J Andrew McCammon,et al.  A molecular dynamics ensemble-based approach for the mapping of druggable binding sites. , 2012, Methods in molecular biology.

[21]  Binh Vu,et al.  Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. , 2013, ACS medicinal chemistry letters.

[22]  Mathias Jucker,et al.  The Amyloid State of Proteins in Human Diseases , 2012, Cell.

[23]  István Simon,et al.  The expanding view of protein–protein interactions: complexes involving intrinsically disordered proteins , 2011, Physical biology.

[24]  Marc-André Delsuc,et al.  Biophysical techniques for ligand screening and drug design. , 2009, Current opinion in pharmacology.

[25]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[26]  Tuomas P. J. Knowles,et al.  The amyloid state and its association with protein misfolding diseases , 2014, Nature Reviews Molecular Cell Biology.

[27]  Giovanna Zinzalla,et al.  Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. , 2012, Journal of the American Chemical Society.

[28]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[29]  D. Teplow,et al.  A peptide hairpin inhibitor of amyloid beta-protein oligomerization and fibrillogenesis. , 2009, Biochemistry.

[30]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[31]  Alexander K. Buell,et al.  Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease , 2014, PloS one.

[32]  Johannes Buchner,et al.  The N-terminal domain of p53 is natively unfolded. , 2003, Journal of molecular biology.

[33]  Michele Vendruscolo,et al.  Identification of small-molecule binding pockets in the soluble monomeric form of the Aβ42 peptide. , 2013, The Journal of chemical physics.

[34]  S. Jones,et al.  Principles of protein-protein interactions. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[36]  Michele Vendruscolo,et al.  Towards complete descriptions of the free–energy landscapes of proteins , 2005, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[37]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[38]  J. Michel,et al.  The Impact of Small Molecule Binding on the Energy Landscape of the Intrinsically Disordered Protein C-Myc , 2012, PloS one.

[39]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[40]  Tuomas P. J. Knowles,et al.  An Analytical Solution to the Kinetics of Breakable Filament Assembly , 2009, Science.

[41]  Michele Vendruscolo,et al.  Determination of conformationally heterogeneous states of proteins. , 2007, Current opinion in structural biology.

[42]  D. Svergun,et al.  Structural analysis of intrinsically disordered proteins by small-angle X-ray scattering. , 2012, Molecular bioSystems.

[43]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[44]  L. Iakoucheva,et al.  Intrinsic disorder in cell-signaling and cancer-associated proteins. , 2002, Journal of molecular biology.

[45]  JoAnne McLaurin,et al.  Small molecule inhibitors of Aβ‐aggregation and neurotoxicity , 2009 .

[46]  C. Dobson The structural basis of protein folding and its links with human disease. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[47]  Laurie E. Grove,et al.  Structural conservation of druggable hot spots in protein–protein interfaces , 2011, Proceedings of the National Academy of Sciences.

[48]  Marc S. Cortese,et al.  Flexible nets , 2005, The FEBS journal.

[49]  Michael H. Hecht,et al.  A Novel Inhibitor of Amyloid β (Aβ) Peptide Aggregation , 2012, The Journal of Biological Chemistry.

[50]  Matthew E Welsch,et al.  Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.

[51]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[52]  Philip J. Hajduk,et al.  Fragment-based lead discovery: challenges and opportunities , 2011, J. Comput. Aided Mol. Des..

[53]  A Keith Dunker,et al.  Unfoldomics of human diseases: linking protein intrinsic disorder with diseases , 2009, BMC Genomics.

[54]  C. Dobson Chemical space and biology , 2004, Nature.

[55]  Horst Kessler,et al.  NMR-based screening: a powerful tool in fragment-based drug discovery. , 2007 .

[56]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[57]  Dmitri I. Svergun,et al.  pE-DB: a database of structural ensembles of intrinsically disordered and of unfolded proteins , 2013, Nucleic Acids Res..

[58]  L. Poppe,et al.  Ordering of the N-terminus of human MDM2 by small molecule inhibitors. , 2012, Journal of the American Chemical Society.

[59]  V. Uversky Unusual biophysics of intrinsically disordered proteins. , 2013, Biochimica et biophysica acta.

[60]  Ariele Viacava Follis,et al.  Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. , 2009, Journal of the American Chemical Society.

[61]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[62]  Martin Blackledge,et al.  Intrinsically Disordered Proteins: From Sequence and Conformational Properties toward Drug Discovery , 2012, Chembiochem : a European journal of chemical biology.

[63]  Dmitri I. Svergun,et al.  Low-resolution structures of transient protein-protein complexes using small-angle X-ray scattering. , 2009, Journal of the American Chemical Society.

[64]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[65]  Wendy A. Warr,et al.  Fragment-based drug discovery , 2009, J. Comput. Aided Mol. Des..

[66]  Liling Zhao,et al.  Novel Strategies for Drug Discovery Based on Intrinsically Disordered Proteins (IDPs) , 2011, International journal of molecular sciences.

[67]  P. Tompa,et al.  Introducing protein intrinsic disorder. , 2014, Chemical reviews.

[68]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[69]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[70]  Christopher J. Oldfield,et al.  Intrinsically disordered proteins in human diseases: introducing the D2 concept. , 2008, Annual review of biophysics.

[71]  S. Metallo,et al.  Intrinsically disordered proteins are potential drug targets. , 2010, Current opinion in chemical biology.

[72]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[73]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[74]  V. Uversky,et al.  Intrinsic Disorder in PTEN and its Interactome Confers Structural Plasticity and Functional Versatility , 2013, Scientific Reports.

[75]  P. Tompa Intrinsically disordered proteins: a 10-year recap. , 2012, Trends in biochemical sciences.

[76]  Michele Vendruscolo,et al.  Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism , 2013, Proceedings of the National Academy of Sciences.

[77]  L. Iakoucheva,et al.  Intrinsic Disorder and Protein Function , 2002 .

[78]  Vladimir N Uversky,et al.  Intrinsically disordered proteins and novel strategies for drug discovery , 2012, Expert opinion on drug discovery.

[79]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[80]  Harald Schwalbe,et al.  Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.

[81]  Ehud Gazit,et al.  Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism , 2006, Chemical biology & drug design.

[82]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.